Business Context and Reporting Period
This Form 8-K is a current report filed by Miragen Therapeutics, Inc. (not Viridian Therapeutics, Inc.) on August 7, 2018. The filing serves to disseminate a press release containing financial results for the three-month period ended June 30, 2018. The registrant is identified as an emerging growth company.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the attached press release (Exhibit 99.1), which is not included in the source text.
Material Changes
The filing does not provide specific data regarding material changes versus prior periods. It solely announces the issuance of the Q2 2018 financial results press release.
Guidance, Outlook, and Risks
The text does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies. The filing explicitly states that the attached press release is furnished under Item 2.02 and is not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into other filings.
Investor Verification Checklist
- Verify the actual financial figures (revenue, net loss, cash position) by reviewing the attached Exhibit 99.1 (Press Release), as they are absent from the 8-K body text.
- Confirm the company name is Miragen Therapeutics, Inc., noting the discrepancy with the "Viridian Therapeutics" label in the request metadata.
- Review the full press release for any forward-looking statements or operational updates not summarized in this 8-K.
- Check subsequent filings for the incorporation of these results into the official 10-Q for the period ended June 30, 2018.